CVM•benzinga•
CEL-SCI Highlights Multikine's 73% 5-Year Survival Benefit In Low PD-L1 Head And Neck Cancer Patients; New Phase 3 Confirmatory Trial Planned With Ergomed As CRO Partner; Accelerated Approval Possible In 2026 Based On Tumor Response Data
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga